Compare Global Payments Inc (GPN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Summit Therapeutics Inc — how do they compare? Global Payments Inc trades at $82.55 (market cap $21.46B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.23% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Summit Therapeutics Inc for 16 Days on average.
| GPN | SMMT | |
|---|---|---|
Market Cap | $21.46B | $13.71B |
Volume | 1,482,600 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $94.83 | $26.38 |
52-Week Low | $62.47 | $12.43 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | $39.60B | $13.04B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% on the day, with a neutral technical signal and bullish moving averages. The stock has beaten EPS estimates for three consecutive quarters, though Q3 2026 results are pending. Revenue declined to $7.71B in 2025, but net income margin improved to 18.16%. Analyst consensus is bullish with a $102.75 price target, representing significant upside. Recent news highlights growth initiatives like the Genius platform and Worldpay integration.
GPN offers potential upside based on strong analyst sentiment and strategic initiatives, but faces risks from rising costs, high debt levels, and competitive pressures. The negative net income margin projection for 2026 underscores execution challenges. Investors should weigh the company's digital payment growth against macroeconomic and operational headwinds.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
